Biovaxys Technology Corp. (BVAXF)
OTC PINK OTC PINK Primary 
BioVaxys DPX-Based Vaccines Exhibit Robust Efficacy Across Multiple Infectious Diseases
VANCOUVER, BC , Aug. 22, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") highlights the potential of its novel lipid-in-oil delivery platform, DPXâ„¢, across multiple infectious disease studies and announces its plans for partnering and further development. BioVaxys' DPXâ„¢ technology ("DPX") is a patented delivery platform that can incorporate a range of bioactive molecules to produce targeted, long-lasting immune responses enabled by various formulated components.
Biovaxys Signs Binding Letter of Intent to Develop DPXâ„¢-Based Vaccines for Life Threatening Food Allergies
VANCOUVER, BC , July 29, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company"), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPXâ„¢ platform, is pleased to announce that it has executed a binding Letter of Intent ("Agreement") with AP Visionaries, Inc. of Ontario ("APVI") to jointly develop a proprietary DPXâ„¢ formulation to address the urgent need for a therapy to treat or alleviate the potentially life-threatening risk of certain food allergies, namely those triggered by exposure to peanut/tree nuts or eggs. APVI is founded by Asha Parekh, CEO of Frontline Medical Technologies, Inc., an Ontario-based medical technologies company, and Adam Power, MD, a vascular surgeon at London Health Sciences Centre, one of Canada's largest acute care teaching hospitals, and Associate Professor, Division of Vascular Surgery, The Schulich School of Medicine & Dentistry at Western University in Ontario.
BIOVAXYS ANNOUNCES ISSUANCE OF DPX RELATED PATENT FROM THE U.S. PATENT AND TRADEMARK OFFICE
VANCOUVER, BC , July 23, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") announced that the United States Patent and Trademark Office ("USPTO") has issued BioVaxys U.S. Patent No. 12,042,537.
BioVaxys Technology Corp. Announces Revocation of Cease Trade Order
VANCOUVER, BC , July 12, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: BVAXF) (the "Company") is pleased to announce the revocation of the failure to file cease trade order (the "FFCTO") issued by its principal regulator, the Ontario Securities Commission (the "OSC"), on May 15, 2024. The FFCTO was issued by the OSC under National Policy 11-207 Failure-to-File Cease Trade Orders and Revocations in Multiple Jurisdictions as a result of the delay in filing the Company's (i) audited annual financial statements for the year ended October 31, 2023, its management's discussion and analysis for the year ended October 31, 2023, and related filings, and (ii) interim financial statements for the three months ended January 31, 2024, its management's discussion and analysis for the three months ended January 31, 2024, and related filings (collectively, the "Required Filings").
BioVaxys Technology Corp. Announces Failure to File Cease Trade Order
VANCOUVER, BC , May 16, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") announces that the Ontario Securities Commission (the "OSC") has issued a failure to file cease trade order ("FFCTO") under National Policy 11-207 Failure-to-File Cease Trade Orders and Revocations in Multiple Jurisdictions ("NP 11-207"), prohibiting the trading by any person of any securities of the Company in Canada, including trades in the Company's common shares made through the Canadian Securities Exchange. The FFCTO was issued as a result of the delay in filing the Company's audited annual financial statements for the year ended October 31, 2023, its management's discussion and analysis for the year ended October 31, 2023, and related filings (collectively, the "Required Annual Filings") and interim financial statements for the three months ended January 31, 2024, its management's discussion and analysis for the three months ended January 31, 2024, and related filings (collectively, the "Required Interim Filings").
CSE Bulletin: Suspension - BioVaxys Technology Corp. (BIOV)
Toronto, Ontario--(Newsfile Corp. - Le 16 mai/May 2024) - Effective immediately, BioVaxys Technology Corp. is suspended pursuant to CSE Policy 3. The suspension is considered a Regulatory Halt as defined in National Instrument 23-101 Trading Rules.
